Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

04 Jan 2018

• By Joseph Haas and Ying Huang

In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

More from Deals

More from Business